Liver Cancer
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1091-1095
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1091
Table 1 Patient characteristics, maximum toxicity, maximum response, adverse events, and arterial hypovascularisation under therapy.
Patient numberAge (yr)GenderMaximum number of gemcitabine cyclesMaximum number of chemo- occlusion cyclesMaximum responseNeutro- penia acc. To WHOThrombo- penia acc. To WHOAnemia acc. To WHOCholes- tasis acc. To WHONausea acc. To WHOFlush symptoms acc. To WHOTumor- related diseaseClinical therapy related benefitProgressive arterial hypovascu- larization
447F73 (+11)PR101122yes-yes
563F92 (+11)PR001211yesyesyes
676F62 (+11)SD000011yesyesyes
Table 2 Present status, chemotherapy-related response and changes of tumor markers.
Patient numberObservervation period (mo)Maximum responseHighest tumor markers beforeLowest tumor marker under therapy (%)Time to tumor progression (mo)Survival therapy (mo)
110SDNone-7Dead (10)
214SDCa15-3:4847 (-21)5Alive
318PRCa19-9:1 44234 (-981)18Alive
412PRCa19-9:8919 (-771)NA (still PR)Alive
AFP:356 (-831)
510PRCa19-9:786139 (-821)NA resected after 10Alive
616SDCa15-3:5443 (-201)7Alive
Ca19-9:88115 (+311)
712SDCa19-9:845 200435 (-991)7
CEA:2852 (-991)Alive
89SDCa15-3:435204 (-531)3
Ca19-9:11784 (-281)Dead (9)